The pharmacological inhibition of the mitogen-activated protein kinase (MAPK) signaling pathway by inhibitors of the BRAF and MEK kinases (BRAFi and MEKi) plays an important role in the treatment of patients with advanced malignant melanoma. Here, MAP2K7 is linked to melanoma.